Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02327169 · ClinicalTrials.gov registry record · Phase 1
A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 81
- Enrollment target
NCT02327169 is a Phase 1 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 81 participants.
The verdict
NCT02327169, a Phase 1 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 81 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine the safety profile and the maximum tolerated doses (MTDs)/ potential recommended phase 2 doses (RP2Ds) of the combination treatments of MLN2480 + MLN0128, MLN2480 + alisertib, MLN2480 + paclitaxel, MLN2480 + cetuximab, and MLN2480 + irinotecan in participants with advanced nonhematologic malignancies.
Interventions
- DRUG Paclitaxel
- DRUG Cetuximab
- DRUG Alisertib
- DRUG MLN0128
- DRUG MLN2480
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2015-01-14 |
| Est. Completion | 2018-07-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02327169
The ClinicalTrials.gov registry entry for NCT02327169 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Paclitaxel is the first listed.
NCT02327169 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02327169 about?
NCT02327169 is a clinical study titled "A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies". The primary purpose of this study is to determine the safety profile and the maximum tolerated doses (MTDs)/ potential recommended phase 2 doses (RP2Ds) of the combination treatments of MLN2480 + MLN0128, MLN2480 + alisertib, MLN2480 + paclitaxel, MLN2480 + cetuximab, and MLN2480 + irinotecan in par...
What is the current status of trial NCT02327169?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 81 participants. The study started on 2015-01-14. Estimated completion is 2018-07-02.
What interventions are being tested in trial NCT02327169?
The interventions under investigation include: Paclitaxel (DRUG), Cetuximab (DRUG), Alisertib (DRUG), MLN0128 (DRUG), MLN2480 (DRUG).
Who is sponsoring clinical trial NCT02327169?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.